Copyright
©The Author(s) 2015.
World J Gastroenterol. May 14, 2015; 21(18): 5445-5453
Published online May 14, 2015. doi: 10.3748/wjg.v21.i18.5445
Published online May 14, 2015. doi: 10.3748/wjg.v21.i18.5445
Table 1 Overview of important clinical trials
First author, Journal (Year) | Study design | Enrollment period | Drugs | Patients | No. Pts |
Santoro, BJC (2013) | Phase I, open-label, single-arm study (full-text), NCT00802555 | 2009.3- 2010.11 completed | Tivantinib | Advanced HCC, Child-Pugh A cirrhosis, previously treated with sorafenib or other therapy | 21 |
Santoro, Lancet Oncol (2013) | Phase II double-blind, placebo-controlled, RCT (full-text), NCT00988741 | 2009.10.8- 2011.8.25 completed | Tivantinib vs placebo | Advanced HCC with or without MET-high tumors, who had progressed on or were unable to tolerate first-line systemic therapy | 107 |
Verslype/Cohn, JCO (2012, May/Feb) | Phase II randomized discontinuation trial (abstract), NCT00940225 | Completed | PR: Continued open-label cabozantinib; SD: Cabozantinib vs placebo; PD: Discontinued | Advanced HCC, ≤ 1 prior systemic regimen, Child-Pugh A | 41 |
Novartis Pharmaceuticals | Phase II, open label, single-arm study (registration), NCT01737827 | Ongoing | INC280 | Advanced HCC which could not be suitable for treatment with locoregional therapies or has progressed following locoregional therapy, c-MET pathway dysregulation | 56 |
Novartis Pharmaceuticals | Phase II, double-blind, placebo-controlled RCT (registration), NCT01964235 | Suspended | INC280 vs placebo | Adult patients with advanced HCC after progression or intolerance to sorafenib treatment, c-MET pathway dysregulation | 69 |
Merck KGaA | Phase Ib/II, single-arm, trial (registration), NCT02115373 | Ongoing | MSC2156119J | Advanced HCC, MET+, Child-Pugh A, who have failed sorafenib treatment | 48 |
Qin, JCO (2014) | Phase Ib/II RCT (abstract), NCT01988493 | Ongoing | Phase II: MSC2156119J vs sorafenib | Asian patients, MET-positive, advanced HCC, Child-Pugh A | 158 |
O'Neil, JCO (2013) | Phase Ib/II, open-label, study (abstract), NCT01271504 | Ongoing | Phase Ib: Golvatinib plus sorafenib; Phase II: Golvatinib plus sorafenib vs sorafenib alone | Advanced HCC | 13 |
Yau, JCO (2012) | Phase I/II trial (abstract), NCT00920192 | Ongoing | Foretinib | Advanced HCC | 13 |
Santoro, JCO (2013) | Phase III, double-blind, RCT (abstract), NCT01755767 | Ongoing | Tivantinib vs placebo | MET diagnostic-high inoperable HCC treated with one prior systemic therapy | 303 |
Abou-Alfa, JCO (2014) | Phase III, double-blind, RCT (abstract), NCT01908426 | Ongoing | Cabozantinib vs placebo | Advanced HCC who have received prior sorafenib | 760 |
- Citation: Qi XS, Guo XZ, Han GH, Li HY, Chen J. MET inhibitors for treatment of advanced hepatocellular carcinoma: A review. World J Gastroenterol 2015; 21(18): 5445-5453
- URL: https://www.wjgnet.com/1007-9327/full/v21/i18/5445.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i18.5445